ZoBio, Domainex Partner to support FORMA Therapeutics’ Drug Discovery Programs
News Dec 08, 2014
The goal of the collaboration is to use ZoBio’s expertise in protein nuclear magnetic resonance (NMR) to elucidate the molecular basis for compound-target interaction, to complement ongoing X-ray crystallography approaches. NMR is currently the only alternative to crystallography capable of elucidating atomic resolution, 3D structural information. Under the agreement, ZoBio will design and express protein variants suitable for structural studies, to support FORMA’s oncology drug discovery research.
In addition, Domainex will apply its Combinatorial Domain Hunting technology to generate suitable protein variants for a selection of particularly challenging targets, not previously amenable to structural studies. Successful targets from the joint ZoBio/Domainex effort will be used for subsequent NMR structural biology studies.
Gregg Siegal, CEO of ZoBio said “We are proud that FORMA, a company with tremendous success in broadly exploring the druggability of target families, has selected ZoBio as a partner. We are excited to provide structural insight where it has not previously been possible.”
Eddy Littler, CEO of Domainex said “We are excited to be working alongside ZoBio to support FORMA in its pursuit of novel cancer drugs. ZoBio and Domainex’s combined technology offering enables previously intractable, but hugely promising drug targets to be tackled; paving the way to a raft of potential new and efficacious oncology drugs.”
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018